PALO ALTO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following healthcare investor conferences: Wells Fargo Healthcare Conference, Boston, MA: Fireside chat on Wednesday, September 3 at 9:30 am ETCantor Global Healthcare Conference – New York, NY: Fireside chat on Thursday, September 4 at ...

Core Insights - Eli Lilly and Company has successfully completed the acquisition of Verve Therapeutics, a clinical-stage company focused on genetic medicines for cardiovascular disease [1] - The acquisition is expected to transform treatment paradigms for millions of patients by providing lifelong cardiovascular risk reduction through a single treatment [2] Company Overview - Eli Lilly has been a pioneer in medical discoveries for nearly 150 years, helping tens of millions globally with its medicines [2] - The company is focused on addressing significant health challenges, including diabetes care, obesity, Alzheimer's disease, immune system disorders, and difficult-to-treat cancers [2] Strategic Implications - The integration of Verve Therapeutics is anticipated to enhance Lilly's capabilities in developing innovative genetic medicines for cardiometabolic diseases [2] - The acquisition aligns with Lilly's mission to make life better for millions by advancing clinical trials and ensuring medicine accessibility [2]

Core Viewpoint - Eli Lilly and Verve Therapeutics have completed a tender offer for Verve's common stock, with a purchase price of $10.50 per share and a contingent value right potentially worth up to $3.00 per share, which expired on July 23, 2025 [1][2]. Group 1: Acquisition Details - The tender offer resulted in 49,882,464 shares being validly tendered, representing approximately 55.7% of the outstanding shares [2]. - All conditions for the acquisition have been satisfied, and Lilly will proceed to pay for the validly tendered shares [2]. - The acquisition is expected to be finalized on July 25, 2025, in accordance with the definitive agreement [3]. Group 2: Company Profiles - Verve Therapeutics is a clinical-stage company focused on developing genetic medicines for cardiovascular diseases, with lead programs targeting key drivers of atherosclerosis [4]. - Lilly is a long-established pharmaceutical company dedicated to advancing healthcare solutions across various significant health challenges, including diabetes, obesity, Alzheimer's disease, and cancer [5].

Core Insights - BridgeBio Pharma, Inc. is set to release its second quarter financial results and business updates on August 5, 2025, after market close [1] - A conference call will be held at 4:30 pm ET on the same day to discuss the financial results and program updates [1] Company Overview - BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, creating, testing, and delivering transformative medicines for genetic diseases [3] - The company was founded in 2015 and has a pipeline that includes programs from early science to advanced clinical trials [3] - BridgeBio's team consists of experienced professionals dedicated to applying advances in genetic medicine to benefit patients [3]

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly making false and misleading statements regarding its gene therapy product ELEVIDYS during the specified Class Period [1][2]. Allegations in the Complaint - Sarepta is accused of misrepresenting the safety of ELEVIDYS, despite serious risks associated with the product [7]. - The company allegedly failed to detect or disclose severe adverse events during clinical trials [7]. - It is claimed that Sarepta withheld material information that led to halted dosing, increased regulatory scrutiny, and suspension of shipments [7]. - The company is also said to have lacked a reasonable basis for positive statements about ELEVIDYS's safety and potential for expanded use [7]. Key Events and Stock Impact - Investors who purchased Sarepta securities during the Class Period and suffered losses have until August 25, 2025, to request the Court to appoint them as lead plaintiff [3].

Core Insights - Regeneron Pharmaceuticals, Inc. will report its second quarter 2025 financial and operating results on August 1, 2025, before U.S. markets open [1] - A conference call and webcast will be held at 8:30 AM Eastern Time on the same day [1][2] Company Overview - Regeneron is a leading biotechnology company focused on inventing, developing, and commercializing life-transforming medicines for serious diseases [3] - The company has a strong pipeline of approved treatments and product candidates, primarily developed in-house, targeting various conditions including eye diseases, cancer, and rare diseases [3] Technological Advancements - Regeneron utilizes proprietary technologies like VelociSuite to produce optimized fully human antibodies and bispecific antibodies [4] - The company leverages data-powered insights from the Regeneron Genetics Center to identify innovative treatment targets and approaches [4]

Company Overview - BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, creating, testing, and delivering transformative medicines for genetic diseases [3] - Founded in 2015, the company has a pipeline that includes programs from early science to advanced clinical trials [3] - The team consists of experienced drug discoverers, developers, and innovators dedicated to applying advances in genetic medicine [3] Upcoming Event - Members of BridgeBio's management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 9 at 8:40 am ET [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible for 30 days post-event [2]

Core Insights - BridgeBio Pharma, Inc. is a biopharmaceutical company focused on genetic diseases, participating in the Bank of America Merrill Lynch Global Healthcare Conference 2025 [1][3] - The company aims to discover, create, test, and deliver transformative medicines for patients with genetic diseases, with a pipeline that includes early science to advanced clinical trials [3] Company Overview - Founded in 2015, BridgeBio is committed to applying advances in genetic medicine to expedite patient care [3] - The company has a team of experienced professionals in drug discovery and development [3] Event Participation - Management will engage in a fireside chat at the conference on May 14, 2025, at 2:20 pm PT [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible for 30 days post-event [2]

Core Insights - Verve Therapeutics announced positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102, showing significant reductions in LDL-C and PCSK9 levels with a single infusion [1][2][10] Efficacy - A single infusion of VERVE-102 resulted in a mean LDL-C reduction of 53% and a maximum reduction of 69% in the 0.6 mg/kg dose cohort [1][11] - The trial demonstrated a dose-dependent response, with mean LDL-C reductions of 21% at 0.3 mg/kg, 41% at 0.45 mg/kg, and 53% at 0.6 mg/kg [11] - Among participants receiving a total RNA dose greater than 50 mg, a mean LDL-C reduction of 59% was observed [9][10] Safety and Tolerability - VERVE-102 was well-tolerated with no treatment-related serious adverse events and no clinically significant changes in liver enzymes or platelets [1][6] - One infusion-related reaction was reported, which was transient and resolved with acetaminophen [6] Clinical Trial Design - The Heart-2 trial is an open-label Phase 1b study evaluating the safety and tolerability of VERVE-102 in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD) [4][5] - The trial includes four dose cohorts, with initial data reported from 14 participants across the first three cohorts [5] Future Plans - Verve plans to report final Heart-2 dose escalation data and initiate a Phase 2 clinical trial for VERVE-102 in the second half of 2025 [1][13] - The company expects to receive a decision from Eli Lilly regarding the PCSK9 opt-in in the second half of 2025 [14] Company Overview - Verve Therapeutics is focused on developing genetic medicines for cardiovascular disease, with VERVE-102 targeting the PCSK9 gene to reduce LDL-C levels [16] - The company aims to transform treatment from chronic therapies to single-course gene editing medicines [16]

Core Insights - Verve Therapeutics has received Fast Track designation from the FDA for its investigational drug VERVE-102, aimed at treating hyperlipidemia and reducing LDL-C levels in patients at high cardiovascular risk [1][2] - VERVE-102 is designed as a single-course treatment that permanently disables the PCSK9 gene in the liver, potentially transforming the management of atherosclerotic cardiovascular disease [1][5] - The company is currently conducting the Phase 1b Heart-2 clinical trial to assess the safety and tolerability of VERVE-102 in patients with heterozygous familial hypercholesterolemia and/or premature coronary artery disease [1][3] Company Overview - Verve Therapeutics is a clinical-stage company focused on developing genetic medicines for cardiovascular diseases, with a goal to shift treatment from chronic therapies to single-course gene editing solutions [5] - The company's lead programs include VERVE-102, VERVE-201, and VERVE-301, targeting key cholesterol drivers associated with atherosclerosis [5] - VERVE-201 aims to turn off the ANGPTL3 gene for patients with refractory hypercholesterolemia, while VERVE-301 targets the LPA gene to reduce Lp(a) levels, an independent risk factor for cardiovascular diseases [5] Clinical Trial Updates - Initial demographic and safety data from the Heart-2 clinical trial are expected to be announced in Q2 2025, including results from three dose cohorts [3] - The final data for the dose escalation portion of the Heart-2 trial is anticipated in the second half of 2025, along with the initiation of the Phase 2 clinical trial for the PCSK9 program [4]